StreetInsider.com News Articles

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

MAPLE GROVE, Minn.--(BUSINESS WIRE)-- Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, and Onconic Therapeutics (KOSDAQ: 476060), a Korea-based biopharmaceutical company, have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO potassium-competitive acid blocker tablets, or P-CAB, treatment for GERD, which affects approximately 20% of the U.S. population. As treatment

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

Thu, 23 Jul 2026 08:15:00 -0400

Bora to manufacture and package clinical trial drug product for JAQBO tablets as Onconic advances U.S. Phase 3 preparation for gastroesophageal reflux disease (GERD)

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)